Blueprint Medicines (BPMC.US) — market event timeline

nashnova tracks 1 market event mentioning Blueprint Medicines (BPMC.US) as of 2026-11-16, each with a dated one-line analysis of how the event relates to the asset.

  1. Eli Lilly Acquires Calytrix Bio for Up to $1.5 Billion, Expanding Blood Cancer Pipeline

    Focused on myeloproliferative neoplasms (including myelofibrosis), targeting the same indications as Calytrix; Lilly's entry could prompt a revaluation of the competitive landscape.

For research and information only — not investment advice.